Ebastine Teva: Uses, Dosage & Side Effects

What Is Ebastine Teva and What Is It Used For?

Ebastine Teva contains the active substance ebastine, a long-acting, selective second-generation histamine H1-receptor antagonist. Unlike first-generation antihistamines such as diphenhydramine and chlorpheniramine, ebastine was specifically designed to preferentially block peripheral H1 receptors with minimal penetration of the blood-brain barrier, resulting in significantly reduced central nervous system side effects such as sedation and cognitive impairment. This pharmacological selectivity represents one of the most important advances in antihistamine therapy over the past several decades.

After oral administration, ebastine is rapidly absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism in the liver, primarily by the cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic process converts ebastine to its pharmacologically active carboxylic acid metabolite, carebastine. It is carebastine, rather than the parent compound ebastine, that is responsible for the vast majority of the therapeutic antihistaminic activity. Carebastine selectively and competitively binds to peripheral H1 histamine receptors on target cells, including those in the nasal mucosa, conjunctival tissue, and skin, thereby preventing histamine from activating the inflammatory cascade that produces allergic symptoms.

Histamine is one of the primary chemical mediators released from mast cells and basophils during an IgE-mediated allergic response. When an individual sensitized to a particular allergen (such as pollen, dust mites, or animal dander) is re-exposed to that allergen, cross-linking of allergen-specific IgE antibodies on the surface of mast cells triggers degranulation and the rapid release of preformed histamine from intracellular granules. This histamine then binds to H1 receptors on various target tissues, causing vasodilation, increased vascular permeability, smooth muscle contraction, mucus secretion, and stimulation of sensory nerve endings. The clinical manifestations of this process include the classic symptoms of allergic rhinitis (sneezing, rhinorrhea, nasal congestion, and pruritus of the nose, palate, and eyes) and urticaria (wheals, erythema, and pruritus of the skin).

By competitively blocking H1 receptors, carebastine effectively prevents histamine from initiating this inflammatory cascade, providing relief from both nasal and ocular symptoms of allergic rhinitis as well as the wheals and itching of urticaria. Clinical studies have demonstrated that ebastine 10 mg administered once daily significantly reduces total symptom scores in patients with seasonal allergic rhinitis, including improvements in sneezing frequency, rhinorrhea severity, nasal pruritus, and ocular itching. In patients with perennial allergic rhinitis, ebastine has shown sustained efficacy over treatment periods of up to 12 weeks, with continued improvement in quality of life measures.

For chronic idiopathic urticaria, ebastine 10 mg once daily has been shown to significantly reduce the number, size, and itching intensity of wheals compared with placebo in randomized controlled trials. The onset of action is typically within one to three hours after oral administration, and the antihistaminic effect is maintained for a full 24 hours, supporting convenient once-daily dosing. The orodispersible tablet formulation offered by Ebastine Teva dissolves rapidly on the tongue, typically within 10 to 30 seconds, without the need for water. This formulation is particularly advantageous for patients with dysphagia (difficulty swallowing), pediatric adolescents, elderly patients, and anyone who needs to take their medication when water is not readily available.

What Should You Know Before Taking Ebastine Teva?

Contraindications

Ebastine Teva must not be used by patients who have a known hypersensitivity (allergic reaction) to ebastine or to any of the excipients contained in the orodispersible tablet formulation. Hypersensitivity reactions to antihistamines, while uncommon, can manifest as urticaria, angioedema, rash, or in very rare cases, anaphylaxis. If you have previously experienced an allergic reaction to ebastine or any product containing ebastine, you should not take this medication.

Ebastine should also not be used in patients with severe hepatic impairment (liver disease). Because ebastine is extensively metabolized by the hepatic CYP3A4 enzyme system, severe liver dysfunction can lead to significantly elevated plasma levels of both the parent compound and its active metabolite carebastine. This increase in drug exposure raises the risk of adverse cardiac effects, particularly QT interval prolongation, which can predispose to potentially life-threatening ventricular arrhythmias including torsades de pointes. Patients with mild to moderate hepatic impairment may use ebastine with caution under medical supervision, but dose adjustments and regular monitoring may be required.

Warnings and Precautions

Ebastine should be used with particular caution in patients with known cardiac conduction abnormalities, including pre-existing QT prolongation on electrocardiogram (ECG), congenital long QT syndrome, or a history of clinically significant cardiac arrhythmias. At therapeutic doses (10 mg), ebastine has not been shown to cause clinically significant QT prolongation in healthy volunteers or in patients with allergic disease. However, at supratherapeutic doses (doses exceeding the recommended 10 mg), or when plasma levels are elevated due to concurrent use of potent CYP3A4 inhibitors, there is a theoretical and documented risk of QT prolongation that warrants caution.

Patients with electrolyte imbalances, particularly hypokalemia (low blood potassium) or hypomagnesemia (low blood magnesium), should have these corrected before starting ebastine therapy, as electrolyte disturbances increase the susceptibility of the cardiac conduction system to drug-induced QT prolongation. Conditions that may predispose to electrolyte imbalances include chronic diarrhea, excessive use of diuretics, chronic kidney disease, and certain endocrine disorders.

Although ebastine is classified as a non-sedating antihistamine, a small proportion of patients may experience mild drowsiness, particularly at the beginning of treatment or when doses are higher than recommended. Patients should be advised to assess their individual response to the medication before engaging in activities that require full alertness, such as driving motor vehicles or operating heavy machinery. The risk of sedation is increased when ebastine is taken concurrently with central nervous system (CNS) depressants, including alcohol, benzodiazepines, opioid analgesics, and other sedating medications.

The orodispersible tablet formulation may contain excipients such as aspartame (a source of phenylalanine), which is relevant for patients with phenylketonuria (PKU). Patients with this condition should check the specific product information for the excipient composition and consult their healthcare provider before use.

Pregnancy and Breastfeeding

There are limited data on the use of ebastine in pregnant women. Animal reproductive toxicity studies conducted in rats and rabbits at doses significantly higher than the recommended human dose did not reveal direct harmful effects on embryonic or fetal development, fertility, or peri- and post-natal development. However, the absence of adverse findings in animal studies does not guarantee safety in human pregnancy, and the clinical data are insufficient to establish the safety of ebastine during pregnancy with certainty.

As a precautionary measure, ebastine should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the fetus. Women of childbearing potential should discuss contraception and the implications of unplanned pregnancy with their prescribing physician before starting treatment. If pregnancy occurs during treatment, the patient should inform her doctor immediately to reassess the benefit-risk balance of continued therapy.

Ebastine and its active metabolite carebastine have been shown to be excreted in breast milk in animal studies. Although the extent of excretion in human breast milk has not been fully characterized, the potential for adverse effects in the breastfed infant cannot be excluded. Therefore, breastfeeding is generally not recommended during treatment with ebastine. If antihistamine therapy is medically necessary during breastfeeding, the prescribing physician should consider alternative antihistamines with a more established safety profile in lactation, such as loratadine or cetirizine, for which more human data are available.

How Does Ebastine Teva Interact with Other Drugs?

The drug interaction profile of ebastine is primarily determined by its metabolic pathway. Ebastine is a prodrug that undergoes extensive hepatic biotransformation via the CYP3A4 enzyme to its active metabolite carebastine. Any drug, food, or substance that significantly inhibits or induces CYP3A4 activity has the potential to alter the plasma concentrations of ebastine and carebastine, thereby affecting both efficacy and safety. Understanding these interactions is essential for safe prescribing and patient management.

Major Interactions

The most clinically significant interactions involve potent inhibitors of CYP3A4. Ketoconazole, a systemic antifungal agent and one of the most potent CYP3A4 inhibitors, has been shown in pharmacokinetic studies to increase the area under the plasma concentration-time curve (AUC) of carebastine by approximately two- to threefold when co-administered with ebastine. This substantial increase in drug exposure has been associated with measurable prolongation of the QTc interval on electrocardiogram, raising concerns about the potential for cardiac arrhythmias. For this reason, concurrent use of ebastine with ketoconazole is generally contraindicated or should only be undertaken with extreme caution and cardiac monitoring.

Itraconazole, another potent azole antifungal, exerts similar CYP3A4 inhibitory effects and carries the same interaction risk as ketoconazole. Macrolide antibiotics, particularly erythromycin and clarithromycin (but not azithromycin, which is a weak CYP3A4 inhibitor), also significantly inhibit CYP3A4 and have been documented to increase carebastine plasma levels. Erythromycin co-administration has been specifically studied and shown to produce clinically relevant increases in carebastine AUC, with associated QTc prolongation. Other potent CYP3A4 inhibitors that may interact with ebastine include ritonavir and other HIV protease inhibitors, nefazodone, and certain calcium channel blockers (diltiazem, verapamil).

Minor Interactions

Grapefruit juice is a well-known dietary inhibitor of intestinal CYP3A4 and has been shown to modestly increase the bioavailability of several CYP3A4 substrates. While no formal pharmacokinetic interaction study has been conducted specifically with ebastine and grapefruit juice, it is prudent to advise patients to avoid consuming large quantities of grapefruit juice during treatment, as it may modestly elevate carebastine levels.

Alcohol does not appear to have a pharmacokinetic interaction with ebastine; however, there is a pharmacodynamic concern. Although ebastine at therapeutic doses is non-sedating, the combination with alcohol may potentially enhance any residual CNS depressant effects, resulting in increased drowsiness or impaired psychomotor function. Patients should be advised to exercise caution with alcohol consumption during treatment.

Cimetidine, an H2-receptor antagonist that is a weak inhibitor of multiple CYP enzymes, has been studied in combination with ebastine and found to produce only modest, clinically insignificant increases in carebastine plasma levels without meaningful QTc prolongation. Similarly, diazepam co-administration has not shown clinically significant pharmacokinetic or pharmacodynamic interactions with ebastine in formal studies. Food, particularly a high-fat meal, can increase the rate and extent of ebastine absorption, leading to higher peak plasma concentrations, although the overall clinical significance of this interaction is minimal at the 10 mg dose.

What Is the Correct Dosage of Ebastine Teva?

Ebastine Teva orodispersible tablets should be placed on the tongue, where they will rapidly disintegrate and dissolve, typically within 10 to 30 seconds. The dissolved tablet can then be swallowed with saliva, and no water is required. Patients should handle the tablet with dry hands to prevent it from dissolving prematurely. The tablet can be taken at any time of day, with or without food, although a consistent dosing time is recommended to maintain stable plasma levels and optimize therapeutic efficacy throughout the 24-hour dosing interval.

Adults

Children

Elderly

Missed Dose

If you forget to take your daily dose of Ebastine Teva, take it as soon as you remember on the same day. If it is nearly time for your next scheduled dose (within a few hours), skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose, as this may increase the risk of side effects including potential cardiac effects at supratherapeutic levels. If you frequently forget doses, consider setting a daily alarm or associating the dose with a routine daily activity (such as breakfast or brushing your teeth) to improve adherence.

Overdose

In cases of overdose with ebastine, symptoms may include drowsiness, headache, dry mouth, dizziness, nausea, and tachycardia. At significantly supratherapeutic doses, there is a potential risk of QT interval prolongation and associated cardiac arrhythmias. There is no specific antidote for ebastine overdose. Treatment is supportive and symptomatic, including gastric decontamination (activated charcoal if the patient presents within one hour of ingestion), continuous cardiac monitoring with ECG, and correction of any electrolyte imbalances. In the event of an intentional or accidental overdose, contact your local poison control center or seek emergency medical attention immediately.

What Are the Side Effects of Ebastine Teva?

Ebastine has been extensively studied in clinical trials involving thousands of patients with allergic rhinitis and chronic urticaria. The overall safety profile at the recommended dose of 10 mg once daily is favorable, with most adverse effects being mild to moderate in severity and transient in nature. In large placebo-controlled trials, the overall incidence of adverse events with ebastine 10 mg was comparable to placebo, underscoring the excellent tolerability of this medication at standard doses.

The following side effects have been reported with ebastine based on clinical trial data and post-marketing surveillance. They are organized by frequency category according to the Medical Dictionary for Regulatory Activities (MedDRA) convention, which classifies adverse reactions by their estimated frequency of occurrence in the treated population.

It is important to distinguish between side effects observed at the standard 10 mg dose and those that are primarily associated with supratherapeutic doses or specific drug interactions. The cardiac effects (QT prolongation, palpitations, tachycardia) are predominantly a concern at doses exceeding 10 mg, in patients with pre-existing cardiac conduction abnormalities, or when ebastine is co-administered with potent CYP3A4 inhibitors. At the 10 mg dose in patients without these risk factors, the cardiac safety profile is reassuring, with no clinically significant difference in QTc interval compared with placebo in controlled studies.

Post-marketing surveillance has not revealed any new or unexpected safety signals beyond those identified in pre-approval clinical trials. The long-term safety of ebastine has been documented in studies lasting up to 12 months, with no evidence of tachyphylaxis (loss of effectiveness over time) or cumulative toxicity. Weight gain, a concern with some antihistamines, has not been associated with ebastine use at therapeutic doses.

How Should You Store Ebastine Teva?

Proper storage of medications is essential to maintain their stability, potency, and safety throughout the intended shelf life. Ebastine Teva orodispersible tablets should be stored at a temperature not exceeding 25°C (77°F). The tablets should be kept in their original blister packaging until immediately before use, as the orodispersible formulation is particularly sensitive to moisture. Exposure to humidity can cause the tablets to degrade, soften, or disintegrate prematurely, which may affect their effectiveness and palatability.

Do not store Ebastine Teva in the bathroom or near a sink, as the humidity in these environments can compromise the tablet integrity. Avoid storing the medication in direct sunlight or near a heat source such as a radiator or in a vehicle dashboard compartment during warm weather. If the medication has been exposed to temperatures significantly above the recommended storage conditions, or if the blister packaging appears damaged or opened, the tablets should be discarded and a new supply obtained.

As with all medications, Ebastine Teva should be kept out of the sight and reach of children to prevent accidental ingestion. When handling orodispersible tablets, ensure that your hands are dry before removing the tablet from the blister pack, as moisture from wet hands can cause the tablet to start dissolving before it is placed on the tongue. After use, check the expiry date on the packaging regularly and return any unused or expired medication to a pharmacy for safe disposal. Do not flush medications down the toilet or dispose of them in household waste, as this can be harmful to the environment.

What Does Ebastine Teva Contain?

The active ingredient in each Ebastine Teva orodispersible tablet is ebastine 10 mg. Ebastine is a white to off-white crystalline powder with the chemical formula C₃₂H₃₉NO₂ and a molecular weight of 469.66 g/mol. It belongs to the piperidine class of antihistamines and is chemically distinct from other second-generation antihistamines such as cetirizine (a piperazine derivative), loratadine (a tricyclic piperidine), and fexofenadine (a piperidine carboxylic acid).

The inactive ingredients (excipients) in the orodispersible tablet formulation serve important pharmaceutical functions. Mannitol, a sugar alcohol, is commonly used as the primary filler and provides a pleasant, slightly sweet taste that enhances patient acceptability of the orodispersible formulation. Microcrystalline cellulose serves as a binder and filler, contributing to the structural integrity of the tablet while still allowing rapid disintegration on the tongue. Crospovidone or croscarmellose sodium functions as a superdisintegrant, enabling the tablet to break apart quickly when it comes into contact with saliva.

Aspartame may be included as a sweetener to improve palatability. Patients with phenylketonuria should be aware that aspartame is a source of phenylalanine and should consult their healthcare provider before use. Flavoring agents are added to provide a pleasant taste during dissolution. Magnesium stearate serves as a lubricant during the manufacturing process, preventing the tablet material from adhering to production equipment. Colloidal silicon dioxide may also be present as a glidant to improve powder flow during manufacture.

The exact excipient composition may vary slightly depending on the country of manufacture and the specific regulatory approvals in each market. Patients with known allergies or intolerances to any pharmaceutical excipients should carefully review the full list of ingredients in the patient information leaflet included with their specific product before use. If you are unsure about any ingredient, consult your pharmacist or prescribing physician for clarification.